At present, interest is also focused on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which are medications able to regulate both lipoprotein (a) and dyslipidemia, and may have a potential in controlling the progression of AS. This evidence concerns the gene PCSK9 and aortic valve stenosis.